TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03539107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde bladder fill
Description: Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spontaneous void
Description: Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
Study: NCT01150630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250 mg/mq/day per os for 14 days every 14 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250 mg/mq/day per os for 14 days every 14 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30 mg/mq every 14 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30 mg/mq every 14 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: 30 mg/mq every 14 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: 30 mg/mq every 14 days for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
Study: NCT01690507

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: 20 mg/m²/day for 5 days

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine

Intervention type: DRUG
Group type: OTHER
Intervention: aclacinomycin

Intervention type: DRUG
Group type: OTHER
Intervention: Granulocyte colony-stimulating factor

Intervention type: OTHER
Group type: OTHER
Intervention: HLA haploidentical mononuclear cells infusion
Study: NCT01838239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
Study: NCT00238407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Cisplatin
Description: Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
Study: NCT03239678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% Oxygen
Description: Conventional preoxygenation with 100% oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Oxygen
Description: preoxygenation with 30% oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21% Oxygen
Description: preoxygenation with 21% oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40% Oxygen
Description: preoxygenation with 40% oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% Oxygen
Description: preoxygenation with 60% oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80% Oxygen
Description: preoxygenation with 80% oxygen
Study: NCT00913549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
Study: NCT01714544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloderm Cream
Study: NCT02037724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement containing 60 mg iron sulfate
Description: control agent

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement containing 60 mg iron sulfate
Description: control agent

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: supplement containing 60 mg iron sulfate
Description: control agent

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron rich food supplement (60 mg iron)
Description: contains 60 mg of iron

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: iron rich food supplement (60 mg iron)
Description: contains 60 mg of iron
Study: NCT02685098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow derived mesenchymal stem cells
Description: Injection of HLA-A2+ and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at 7 days before amputation.
Study: NCT04195139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
Study: NCT03623945

Intervention type: OTHER
Intervention: Collection of blood
Description: Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer

Intervention type: OTHER
Intervention: Collection of blood
Description: Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer
Study: NCT02037724

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: iron rich food supplement (60 mg iron)
Description: contains 60 mg of iron

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron rich food supplement (10 mg iron)
Description: contains 10 mg iron
Study: NCT03623945

Intervention type: OTHER
Intervention: Collection of blood
Description: Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer

Intervention type: OTHER
Intervention: Collection of blood
Description: Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer

Intervention type: OTHER
Intervention: Collection of blood
Description: Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer
Study: NCT02037724

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: iron rich food supplement (10 mg iron)
Description: contains 10 mg iron

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: iron rich food supplement (10 mg iron)
Description: contains 10 mg iron

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement containing 10 mg iron sulfate
Description: control agent

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement containing 10 mg iron sulfate
Description: control agent

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: supplement containing 10 mg iron sulfate
Description: control agent
Study: NCT03729050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Coordinator in Specialist Psychiatry
Description: Rehabilitation Coordinator service in Specialist Psychiatry
Study: NCT02697214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Charge HR
Description: Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch
Description: Apple Watch heart rate monitoring device compared to ECG and Polar H7

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mio Fuse
Description: Mio Fuse heart rate monitoring device compared to ECG and Polar H7

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Basis Peak
Description: Basis Peak heart rate monitoring device compared to ECG and Polar H7
Study: NCT04180488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration
Study: NCT02942277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA
Description: The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA
Description: The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
Study: NCT02597517

Intervention type: DEVICE
Intervention: Digital chromoendoscopy and magnification
Description: After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits

Intervention type: DEVICE
Intervention: Digital chromoendoscopy and magnification
Description: After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
Study: NCT01095497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE
Description: C1 esterase inhibitor (human)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE
Description: C1 esterase inhibitor (human)
Study: NCT03645642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine 5 mg thrice daily

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin 20g/l

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Albumin 20g/l

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics
Description: Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics
Description: Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
Study: NCT03485443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %0.9 NaCl 10ml/kg
Description: Fluid administration
Study: NCT02942277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA
Description: The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA
Description: The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
Study: NCT03485443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %0.9 NaCl 20ml/kg
Description: Fluid administration
Study: NCT02942277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
Study: NCT00004244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study: NCT00004244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study: NCT05036213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice
Description: Each bottle contains 75ml of concentrated beetroot juice with approximately 6.2mmol of inorganic nitrate. The product is provided by BEET IT, James White Drinks, Ipswich, UK.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice (nitrate depleted)
Description: Each bottle contains 75ml of concentrated beetroot juice with depleted nitrate, thus, no inorganic nitrate is found in thisbeverage. The product is also provided by BEET IT, James White Drinks, Ipswich, UK.
Study: NCT03080740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin palmitate hydrochloride dispersible tablet
Description: 300mg, oral after meal, twice daily, a total of 7days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Tablet
Description: 400mg, oral after meal , twice daily, a total of 7days
Study: NCT02546648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin or matching placebo
Description: Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
Study: NCT00600093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery
Study: NCT05606861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Interventions in Pediatric Nurses
Description: This intervention are structured mindfulness program including meditation and breathing techniques .
Study: NCT04102618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: 4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: 4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: 4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: 4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: 4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: 4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Oral dose of 2.5 mg/day starting on Day 3 for 13 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Oral dose of 2.5 mg/day starting on Day 3 for 13 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered intravenously on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered intravenously on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered intravenously on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered intravenously on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg administered intravenously or 600mg subcutaneously on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Study: NCT02942277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
Study: NCT04102618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Study: NCT00999505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Amantadine 200mg twice a day over 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice a day over 12 weeks